✦ LIBER ✦

Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity

✍ Scribed by Harold Lau; Sony Brar; Desiree Hao; Jack MacKinnon; Don Yee; Stefan Gluck

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 159 KB
Volume: 28
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.20324

No coin nor oath required. For personal study only.

✦ Synopsis

Background. Our center sought to implement a simple chemoradiotherapy schedule for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) with minimal toxicity to achieve rates of overall survival comparable to other schedules.

Methods. The chemoradiotherapy schedule consisted of daily radiation to 70 Gy over 7 weeks with concurrent cisplatin 20 mg/m 2 during days 1 to 4 of weeks 1 and 5. Acute and late toxicities were recorded according to the Radiation Therapy Oncology Group (RTOG) and common toxicity criteria (CTC) grading. The overall, disease-specific, and locoregional recurrence -free survival were calculated using the STATA statistics package. Possible factors influencing these endpoints were analyzed.

Results. Fifty-seven patients were treated, and 56 patients were evaluable for follow-up. Median follow-up of alive patients was 16.1 months. There was an 82% complete response rate to chemoradiotherapy. The 2-year Kaplan -Meier overall, disease-specific, and locoregional recurrence -free survival rates were 62%, 67%, and 63%. Acute grade 3 and 4 radiation toxicity was noted in 61% and 2%, respectively. Grade 3 or 4 hematologic toxicity was noted in 7% of patients. Factors influencing overall survival included: Karnofsky performance status, receiving more than 50% of planned chemotherapy, age, and initial hemoglobin level.

Conclusion. This regimen is tolerable and achieves overall survival and locoregional control rates comparable to other chemoradiotherapy schedules.

📜 SIMILAR VOLUMES

Prognostic significance of p16 in locall

Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy

✍ Harold Y. Lau; Sony Brar; Alexander C. Klimowicz; Stephanie K. Petrillo; Desirée 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB 👁 1 views

## Abstract ## Background Human papillomavirus (HPV)–related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status. ## Methods p16 immunohistochemistry (IHC) was assessed in archival pa

Cisplatin, tegafur, and leucovorin : A m

Cisplatin, tegafur, and leucovorin : A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck

✍ Hung-Ming Wang; Cheng-Su Wang; Jen-Shi Chen; I-How Chen; Chun-Ta Liao; Tung-Chie 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Abstract ## BACKGROUND To evaluate the efficacy and toxicity of cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy (CT) for patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN). ## METHODS Patients with SCCHN according to World Health Organiza

Predictors of response and survival afte

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck

✍ Mohan Suntharalingam; Michael L. Haas; David A. Van Echo; Robert Haddad; Maria C 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

High-dose intra-arterial cisplatin and c

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study

✍ William F. Regine; Joseph Valentino; William John; Gayle Storey; David Sloan; Da 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

Phase I and initial phase II results fro

Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck

✍ David L. Schwartz; R. Bruce Montgomery; Bevan Yueh; Michael Donahue; Yoshimi Anz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB‐XRT) for locally advanced head and neck squamous cell carcinoma. ## METHODS Twenty patients wi

Quality-adjusted survival analysis of Ra

Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma

✍ Andre A. Konski; Kathryn Winter; Bernard F. Cole; Kie-Kian Ang; Karen K. Fu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

## Abstract ## Background. To evaluate quality‐adjusted survival (QAS) of patients with locally advanced squamous cell carcinoma of the head and neck treated with 4 different radiation fractionation schedules. ## Methods. QAS was calculated using the quality‐adjusted time without toxicity or rel